26 Aug 2015

Publication: Inhibition of NOX1/4 with GKT137831: potential novel treatment for a variety of vision-threatening retinopathies

Dr Devy Deliyanti and Prof Jennifer Wilkinson-Berka
with Devy's PhD thesis. 
Inflammation and the excess production of reactive oxygen species (ROS) contribute significantly to the pathogenesis of ischemic retinopathies such as diabetic retinopathy and retinopathy of prematurity. Department of Immunology's Prof Jennifer Wilkinson-Berka and Dr Devy Deliyanti have hypothesized that GKT137831, a dual inhibitor of NADPH oxidases (NOX) 1 and NOX4, reduces inflammation in the ischemic retina by dampening the pro-inflammatory phenotype of retinal immune cells as well as macroglial Müller cells and neurons. They have concluded that NOX1/4 enzyme inhibition with GKT137831 has potent anti-inflammatory effects in the retina, indicating its potential as a treatment for a variety of vision-threatening retinopathies.

Reference: Deliyanti D, Wilkinson-Berka JL. Inhibition of NOX1/4 with GKT137831: A potential novel treatment to attenuate neuroglial cell inflammation in the retina. J Neuroinflammation. 2015 Jul 30;12:136.Link

No comments:

Post a comment

Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.

Related Posts Plugin for WordPress, Blogger...